<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="870">
  <stage>Registered</stage>
  <submitdate>3/11/2005</submitdate>
  <approvaldate>4/11/2005</approvaldate>
  <actrnumber>ACTRN12605000712606</actrnumber>
  <trial_identification>
    <studytitle>Adjuvant GIST Trial</studytitle>
    <scientifictitle>Intermediate and high risk localised, completely resected, gastrointestinal stromal tumours (GIST) expressing KIT recepto: a controlled randomised trial on adjuvant Imatinib mesylate (Glivec) versus no further therapy after complete surgery</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>National Clinical Trials Registry: NCTR553</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal stromal tumours (GIST)</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Stomach</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Imatinib mesylate (400mg/day) for two years</interventions>
    <comparator>No further anti-tumour therapy</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to Imatinib Failure. This information will be collected from medical records.</outcome>
      <timepoint>Until Progression of disease. This information will be collected from medical records.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse-free survival. This information will be collected from medical records.</outcome>
      <timepoint>Until relapse of patient.  This information will be collected from medical records.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Relapse-free interval. This information will be collected from medical records.</outcome>
      <timepoint>Until first patient relapse. This information will be collected from medical records.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Adverse events. This information will be collected from medical records.</outcome>
      <timepoint>Until occurance of an adverse event. This information will be collected from medical records.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Overall Survival. This information will be collected from medical records.</outcome>
      <timepoint>Until patient death.  This information will be collected from medical records.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically proven diagnosis of GIST (positive for CD117), intermediate or high risk of relapse documented on surgical specimen, surgery performed between 2 weeks and 3 months before treatment start , non evidence of residual macroscopic disease after surgery (R0 or R1 resection only), no prior treatment for GIST (ie. radiotherapy, chemotherapy, molecular targeted therapy, biological therapy), absence of distant metastases, WHO performance status 0-2.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>No exclusion criteria</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>N/A</concealment>
    <sequence>Randomisation will be performed using the EORTC Online Randomised Trial Access (ORTA) system. A minimisation technique will be used for random treatment allocation stratifying for center, risk category (high vs. intermediate), tumour site (gastric vs. other) and resection level (R0 vs. R1)</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>4/11/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>400</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other Collaborative groups</primarysponsortype>
    <primarysponsorname>AGITG</primarysponsorname>
    <primarysponsoraddress>6-10 Mallett Street Camperdown, NSW 2050</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>multi-state Cancer Council grant</fundingname>
      <fundingaddress>153 Dowling Street 
Woolloomooloo, NSW 2011</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>industry</fundingname>
      <fundingaddress>Avenue Mounierlaan, 83/11
Brussel 1200 Bruxelles  Belgium</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Novartis Pharmaceuticals Pty Limited</sponsorname>
      <sponsoraddress>54 Waterloo Road
North Ryde NSW 2113</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Dusan Kotasek</name>
      <address>Ashford Cancer Centre Research
Level 1, Tennyson Centre
520 South Road
Kurralta Park 
South Australia 5037</address>
      <phone>+61 8 8292 2240</phone>
      <fax>+61 8 8292 2241</fax>
      <email>dkotasek@adelaidecancercentre.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Adjuvant GIST Trial Coordinator</name>
      <address>National Health and Medical Research Council (NHMRC) Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450</address>
      <phone>+61 2 95625000</phone>
      <fax>+61 2 95625094</fax>
      <email>adjgist@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Adjuvant GIST Trial Coordinator</name>
      <address>Locked Bag 77 Camperdown NSW 1450</address>
      <phone>(02) 9562 5000</phone>
      <fax>(02) 9562 5094</fax>
      <email>adjgist@ctc.usyd.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>